Physician profile
Ammar Hemaidan
NPI 1033149752
$8,993.68
in general payments reported to CMS, 2019-2025
26 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,450 · 2020: $125 · 2021: $42.10 · 2022: $156 · 2023: $314 · 2024: $546 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $5,689.41 | 2019-2023 | Capsocam Plus |
| Capsopro Services LLC | $1,200.00 | 2019 | |
| Abbvie INC. | $521.83 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $281.82 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $235.27 | 2019-2025 | Exalt Model D, Spyglass |
| Janssen Scientific Affairs, LLC | $223.68 | 2019 | |
| Janssen Biotech, INC. | $212.00 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $154.86 | 2019-2021 | |
| Ethicon US, LLC | $118.25 | 2019 | |
| Olympus America INC. | $110.55 | 2024 | Evis Exera III Colonovideoscope |
| Ambu INC. | $80.89 | 2020 | |
| Pentax of America, INC. | $44.11 | 2020 | |
| Intercept Pharmaceuticals, INC. | $34.36 | 2019-2024 | |
| Genzyme Corporation | $22.38 | 2025 | |
| Merck Sharp & Dohme LLC | $17.10 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.00 | 2019 | |
| Celgene Corporation | $15.85 | 2019 | |
| Allergan, INC. | $15.32 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Hemaidan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.